Abstract: The present invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as pharmaceutical compositions, preparation methods, and uses thereof. The MAGL small molecule inhibitors are represented by formula (I), with specific substituents and definitions as described in the specification. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. The invention includes these compounds or their pharmaceutical compositions for the treatment and/or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and/or pain-associated spasticity.

Abstract: The present disclosure relates to a composition capable of promoting hair growth, including a pulchinenoside active component of pulchinenoside B4 or pulchinenoside B5. The experiment results are showed that the composition of the present disclosure can promote hair growth in a hair removal area of mice, improve its growth speed and increase the number of hair follicles, and has non-toxic side effects, low cost and rapid curative effect. The present disclosure also discloses a drug capable of promoting hair growth, including a pulchinenoside active component of pulchinenoside B4 or pulchinenoside B5. The present disclosure also discloses pulchinenoside B4 or pulchinenoside B5 as an active component in preparation of the composition or drug capable of promoting hair growth.

Abstract: A device for measuring a wall surface cooling characteristic of a gas turbine combustor and a modeling method thereof are provided. The device includes a hot flow inlet section, a cold flow inlet section, and a gas discharge section, where the cold flow inlet section is communicated with an experimental section; the cooling structure model is a flat plate structure; a tail end of the experimental section is provided with a thermocouple threading seat; the gas discharge section is provided with a laser injection window; and the experimental section is provided with an infrared thermal imaging measurement window and a visual observation window. The modeling method includes: modeling the wall surface of the gas turbine combustor into the flat plate structure; determining a pressure, a temperature, and a velocity on a hot flow side of the device; and determining a material and a thickness of the cooling structure model.

Abstract: The present disclosure relates to an application of anemoside B4 in preparation of drug for treatment or prevention of psoriasis. Anemoside B4 has therapeutic effect on 5% imiquimod-induced psoriatic lesions in mice. Its possible mechanism may be inhibiting inflammation reactions, regulating immune function and inhibiting angiogenesis, and the therapeutic effect may be realized by inhibiting the release of IL-12, IL-17, IL-6 and IL-1? in skin tissue. This study of the present disclosure laid a theoretical foundation for the subsequent development of anemoside B4 into an anti-psoriasis drug of traditional Chinese medicine.

Abstract: Use of the compound Pulsatilla Saponin B4 represented by formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases, and a medicament comprising the compound Pulsatilla Saponin B4 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease is dairy cow mastitis.

Abstract: The present disclosure relates to an application of anemoside B4 in preparation of drug for treatment or prevention of psoriasis. Anemoside B4 has therapeutic effect on 5% imiquimod-induced psoriatic lesions in mice. Its possible mechanism may be inhibiting inflammation reactions, regulating immune function and inhibiting angiogenesis, and the therapeutic effect may be realized by inhibiting the release of IL-12, IL-17, IL-6 and IL-1? in skin tissue. This study of the present disclosure laid a theoretical foundation for the subsequent development of anemoside B4 into an anti-psoriasis drug of traditional Chinese medicine.

Abstract: Disclosed are uses of a Pulsatilla saponin compound B4 or a pharmaceutically acceptable salt thereof in preparing a drug for treating viral and/or bacterial diseases. The Pulsatilla saponin compound B4 disclosed by the invention shows a strong biological activity, and efficiently treats endometritis, footrot, feline parvovirus, canine parvovirus, canine distemper, canine kidney failure, and canine acute nephritis.

Abstract: Use of the compound Pulsatilla Saponin B4 represented by formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases, and a medicament comprising the compound Pulsatilla Saponin B4 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease is dairy cow mastitis.

Abstract: Disclosed are uses of a Pulsatilla saponin compound B4 or a pharmaceutically acceptable salt thereof in preparing a drug for treating viral and/or bacterial diseases. The Pulsatilla saponin compound B4 disclosed by the invention shows a strong biological activity, and efficiently treats endometritis, footrot, feline parvovirus, canine parvovirus, canine distemper, canine kidney failure, and canine acute nephritis.

Abstract: Use of the compound Pulsatilla Saponin B4 represented by formula (I), or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating viral and/or bacterial diseases, and a medicament comprising the compound Pulsatilla Saponin B4 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease is dairy cow mastitis.

Abstract: The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.

Abstract: The present invention discloses a ziyuglycoside II polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 20 parts of ziyuglycoside II and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of ziyuglycoside II polymer micelle prepared is the best, but using other additional materials can lead to the lowered preparation quality. In the pharmacodynamic experiment, compared with the model group, the ziyuglycoside II micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug ziyuglycoside II, indicating the ziyuglycoside II polymer micelle of the present invention has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug ziyuglycoside II.

Abstract: The present invention discloses a ziyuglycoside II polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 20 parts of ziyuglycoside II and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of ziyuglycoside II polymer micelle prepared is the best, but using other additional materials can lead to the lowered preparation quality. In the pharmacodynamic experiment, compared with the model group, the ziyuglycoside II micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug ziyuglycoside II, indicating the ziyuglycoside II polymer micelle of the present invention has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug ziyuglycoside II.

Abstract: The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.

Abstract: A vertical door locking system includes a door lock with a deadbolt that moves horizontally, a striker with an upward facing strike opening that vertically receives the deadbolt and a lock controller. The striker includes an electrically operated catch to engage and release the deadbolt. The door lock and striker are mounted opposite each other, one to the vertical door and the other to an adjacent fixed mounting point. The lock controller electrically operates the striker to release the deadbolt and allow it to move vertically out of engagement with the striker for primary access to a secure area and the door lock allows the deadbolt to be retracted horizontally away from the striker for secondary access. A remotely located control system optionally controls the lock controllers of multiple doors and a central office control system is optionally connected to multiple remotely located control systems.

Abstract: A vertical door locking system includes a door lock with a deadbolt that moves horizontally, a striker with an upward facing strike opening that vertically receives the deadbolt and a lock controller. The striker includes an electrically operated catch to engage and release the deadbolt. The door lock and striker are mounted opposite each other, one to the vertical door and the other to an adjacent fixed mounting point. The lock controller electrically operates the striker to release the deadbolt and allow it to move vertically out of engagement with the striker for primary access to a secure area and the door lock allows the deadbolt to be retracted horizontally away from the striker for secondary access. A remotely located control system optionally controls the lock controllers of multiple doors and a central office control system is optionally connected to multiple remotely located control systems.